STOCK TITAN

Equillium Q3 2026 net loss widens to $4.6M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Equillium, Inc. reported a third-quarter 2026 net loss of $4.6 million, or $(0.04) per basic and diluted share, versus a $4.2 million net loss, or $(0.06) per share, in 2025. R&D expense was $2.5 million versus $1.3 million; G&A expense was $2.6 million versus $3.3 million. Cash and equivalents were $53.3 million as of September 30, 2026. The October 26 private-placement tranche generated approximately $20 million in gross proceeds; pro forma cash after estimated net proceeds was approximately $72.0 million as if received September 30, excluding cash used thereafter. Equillium expects cash and October funding to support planned operations into 2029.

In October 2026, Equillium initiated a randomized, double-blind, placebo-controlled Phase 1 trial of EQ504 in Australia, evaluating single and multiple ascending doses in approximately 70 healthy participants. The trial assesses safety, tolerability, pharmacokinetics and pharmacodynamics and is designed to establish proof of mechanism. Multiple-dose participants undergo gastrointestinal mucosal biopsies, including CYP1A1 measurement. Topline data are expected in Q2 2027. Subject to supportive results, Equillium plans a placebo-controlled proof-of-concept study in moderately to severely active ulcerative colitis in the second half of 2027.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNet loss: $4.6 million versus $4.2 million in the same quarter of 2025.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash and cash equivalents $53.3 million As of September 30, 2026
Pro forma cash and cash equivalents Approximately $72.0 million After estimated net proceeds from October funding, presented as if received on September 30, 2026
Gross proceeds Approximately $20 million October 26, 2026 private-placement tranche
Research and development expenses $2.5 million Third quarter 2026, compared with $1.3 million in the third quarter of 2025
General and administrative expenses $2.6 million Third quarter 2026, compared with $3.3 million in the third quarter of 2025
Net loss $4.6 million Third quarter 2026, compared with $4.2 million in the third quarter of 2025
Net loss per basic and diluted share $(0.04) Third quarter 2026, compared with $(0.06) in the third quarter of 2025
Phase 1 trial participants Approximately 70 healthy participants EQ504 trial in Australia
aryl hydrocarbon receptor (AhR) modulator medical
"EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator"
pharmacokinetics medical
"characterize safety, tolerability, pharmacokinetics and pharmacodynamics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
pharmacodynamics medical
"characterize safety, tolerability, pharmacokinetics and pharmacodynamics"
Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.
CYP1A1 expression technical
"including measurement of CYP1A1 expression"
proof-of-mechanism medical
"including proof-of-mechanism assessments"
Proof-of-mechanism is early clinical or laboratory evidence that a medicine or therapy is affecting the specific biological target or pathway it was designed to hit, typically shown through measurable changes in biomarkers or physiological signals. For investors, it matters because it reduces scientific uncertainty—like confirming a tool actually moves the intended part of a machine—helping decide whether a drug candidate is worth further development, partnership, or funding.
delayed-release medical
"oral, colon-targeted delayed-release drug product"
A delayed-release drug formulation is engineered so the active ingredient is released at a later point after administration rather than immediately on swallowing; this is typically achieved with coatings or internal barriers that prevent release until a specific time or location in the digestive tract (for example, after passing the stomach). It differs from extended‑ or sustained‑release formulations, which spread drug release over an extended period; delayed‑release creates a lag before release, while extended‑release controls the rate of release. The term does not specify how long the delay is or the exact release site, which are determined by the product’s design and regulatory labeling.
Cash and cash equivalents $53.3 million Compared with $33.1 million as of September 30, 2025
Research and development expenses $2.5 million Compared with $1.3 million in the same period of 2025
General and administrative expenses $2.6 million Compared with $3.3 million in the same period of 2025
Net loss $4.6 million Compared with $4.2 million in the same period of 2025
Net loss per basic and diluted share $(0.04) Compared with $(0.06) in the same period of 2025
Guidance

Equillium believes cash and cash equivalents as of September 30, 2026, together with additional funding received in October, are sufficient to fund currently planned operations into 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was EQ’s third-quarter 2026 net loss?

Equillium reported a net loss of $4.6 million, or $(0.04) per basic and diluted share, compared with a $4.2 million net loss, or $(0.06) per share, in the third quarter of 2025.

What does EQ504’s Phase 1 trial measure?

The Australian trial evaluates single and multiple ascending doses in approximately 70 healthy participants. It is designed to characterize safety, tolerability, pharmacokinetics and pharmacodynamics and establish proof of mechanism. The multiple-dose portion includes longitudinal gastrointestinal mucosal biopsies, including measurement of CYP1A1 expression.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000174646600017464662026-11-122026-11-12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

Equillium, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

001-38692

82-1554746

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

2223 Avenida de la Playa

Suite 105

La Jolla, CA

 

 

 

92037

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 240-1200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

EQ

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 12, 2026, Equillium, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibit

Number

Description.

99.1

Press release, dated November 12, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EQUILLIUM, INC.

 

 

Date: November 12, 2026

By: /s/ Bruce D. Steel

 

Bruce D. Steel

 

Chief Executive Officer

 

 

 

 

 


Exhibit 99.1

img162018617_0.jpg

 

Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights

 

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027

Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026

 

Cash runway expected into 2029

 

LA JOLLA, California, November 12, 2026 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting recent progress with EQ504, its novel small-molecule aryl hydrocarbon receptor (AhR) modulator.

 

“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,” said Bruce Steel, Chief Executive Officer of Equillium. “We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease. We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”

 

Recent Corporate and Clinical Highlights:

Initiated Phase 1 clinical trial of EQ504
In October 2026, Equillium initiated a first-in-human, randomized, double-blind, placebo-controlled study in Australia evaluating single and multiple ascending doses of EQ504 in approximately 70 healthy participants. The trial is designed to characterize safety, tolerability, pharmacokinetics and pharmacodynamics, and establish proof of mechanism of EQ504. The multiple ascending dose portion will include longitudinal gastrointestinal mucosal biopsies, including measurement of CYP1A1 expression, to assess AhR target engagement and localized biological activity in the gastrointestinal tract. Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027. Subject to supportive results, Equillium plans to initiate a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.

Milestone Closing of $20 Million Financing
On October 26, 2026, concurrent with the first patient dosed in the Phase 1 clinical trial, Equillium closed the second tranche of the Company's previously announced August 2025 equity private placement agreement, resulting in aggregate gross proceeds of approximately $20 million.

 

 

 


img162018617_1.jpg

 

Presented new nonclinical data further characterizing EQ504’s effects on epithelial barrier repair and immune regulation
Data presented at the 7th International AHR Conference demonstrated EQ504’s activity across complementary epithelial and immune pathways relevant to intestinal inflammation, including effects on barrier integrity, inflammatory chemokine production and immune regulation. Additional data presented at the 50th Anniversary La Jolla Immunology Conference further characterized coordinated AhR signaling across epithelial and immune compartments, supporting the potential of EQ504 to restore intestinal homeostasis through a differentiated, non-immunosuppressive mechanism of action.

 

Third Quarter 2026 Financial Results:

Cash and cash equivalents totaled $53.3 million as of September 30, 2026, compared to $33.1 million as of September 30, 2025. In October 2026, first participant dosing in the Phase 1 clinical trial of EQ504 triggered the second tranche of the Company’s previously announced August 2025 private placement agreement, resulting in approximately $20 million in additional funding. On a pro forma basis, after giving effect to the estimated net proceeds from this subsequent funding as if received on September 30, 2026, cash and cash equivalents would have been approximately $72.0 million. The pro forma amount is presented for supplemental informational purposes only and does not reflect cash used after September 30, 2026. Equillium believes that its cash and cash equivalents on the balance sheet as of September 30, 2026, together with the additional funding received in October 2026, are sufficient to fund its currently planned operations into 2029.

 

Research and development (R&D) expenses for the third quarter of 2026 were $2.5 million, compared with $1.3 million for the same period in 2025.

 

General and administrative (G&A) expenses for the third quarter of 2026 were $2.6 million, compared with $3.3 million for the same period in 2025.

 

Net loss for the third quarter of 2026 was $4.6 million, or $(0.04) per basic and diluted share, compared with a net loss of $4.2 million, or $(0.06) per basic and diluted share for the same period in 2025.

 

About EQ504

EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal immunoregulatory mechanism of action without broad immune suppression, designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. Equillium is also evaluating the potential of EQ504 for additional indications, including inflammatory lung diseases through inhaled formulations.

 

About Equillium

Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat serious autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.

 

 


img162018617_1.jpg

 

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential”, “will”, “designed to” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for reporting data from the Phase 1 study of EQ504; the potential benefits of EQ504, including its potential ability to address key epithelial and immune pathways involved in inflammatory disease; the anticipated initiation of a placebo-controlled proof-of-concept study, or the expected timeline for initiating such study, in patients with ulcerative colitis; the expected use of proceeds from the Milestone Closing; and Equillium’s expectations that its financial position and cash runway is sufficient to fund its currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and nonclinical studies; risks associated with relying on pro forma financial information; whether the results from clinical and nonclinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com 

 

 

 


img162018617_1.jpg

 

img162018617_2.jpg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


img162018617_1.jpg

 

img162018617_3.jpg

 


Filing Exhibits & Attachments

2 documents

Keep reading